Prospective study of 465 COVID-19 ICU patients in Libya showing no significant differences with treatment.
risk of death, 23.4% lower, RR 0.77, p = 0.29, treatment 7 of 15 (46.7%), control 274 of 450 (60.9%), NNT 7.0.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta
unadjusted results with no group details.
Elhadi et al., 4/30/2021, prospective, Libya, Africa, peer-reviewed, 21 authors, study period 29 May, 2020 - 30 December, 2020, dosage not specified.